Mitiglinide

• Description :

  Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel) . Mitiglinide can be used for the research of type 2 diabetes[1][2].

• Product Name Alternative :

  KAD-1229 (free acid anhydrous) ; S21403 (free acid anhydrous)

• UNSPSC :

  12352005

• Hazard Statement :

  H302-H315-H319

• Target :

  Potassium Channel

• Type :

  Reference compound

• Related Pathways :

  Membrane Transporter/Ion Channel

• Applications :

  Metabolism-sugar/lipid metabolism

• Field of Research :

  Metabolic Disease

• Assay Protocol :

  https://www.medchemexpress.com/mitiglinide.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(N1C[C@@](CCCC2)([H])[C@@]2([H])C1)C[C@@H](C(O)=O)CC3=CC=CC=C3

• Molecular Formula :

  C19H25NO3

• Molecular Weight :

  315.41

• Precautions :

  P264-P270-P280-P302+P352-P305+P351+P338-P330-P362+P364-P501

• References & Citations :

  [1]Y Sunaga, et al. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Eur J Pharmacol. 2001 Nov 9;431 (1) :119-25.|[2]Kiyoshi Ichikawa, et al. Effect of KAD-1229, a novel hypoglycaemic agent, on plasma glucose levels after meal load in type 2 diabetic rats. Clin Exp Pharmacol Physiol. May-Jun 2002;29 (5-6) :423-7.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• CAS Number :

  [145375-43-5]